Comprehensive Hereditary Panels-Hereditary Pancreatic Cancer
Unique Identifier:
ML-N004
Name on Requisition:
Comprehensive Hereditary Panels-Hereditary Pancreatic Cancer
Product Line:
NH
Panel Group:
Hereditary Cancer Panels
Panel Name:
Comprehensive Hereditary Panels-Hereditary Pancreatic Cancer
Methodology
Molecular
NGS
Test Description and clinical significance
Genes
APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, SMAD4, STK11, TP53, VHL
Disease:
Pancreatic Cancer
The Hereditary Pancreatic Cancer Panel evaluates germline mutations in genes linked to familial pancreatic cancer susceptibility, such as BRCA1, BRCA2, PALB2, CDKN2A, STK11, and ATM. Results provide information on cancer predisposition, family risk, and therapeutic relevance, including eligibility for targeted treatments and enhanced surveillance programs.
Specimen Requirements
Preparation:
PB, saliva
Collection:
Specimen should contain least 0.5 mL of peripheral blood (lower volumes may be accepted if situation demands), but we prefer larger specimens in case of a low content of nucleated cells. For saliva, it is recommended to request 1.5-2.0 ml of saliva to be collected from each patient.
Stability:
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
CPT(s)
81432
New York Approved
Yes
TAT
14-21
Requisition Type
NH
Levels of Service
Full
DexS Code
Z03QH
Prefix
MI
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
